Mode
Text Size
Log in / Sign up
N/A N=110 Randomized Triple-blind Treatment

Analgesia in Laparoscopic Cholecystectomy

Pain, Postoperative · Chronic Postoperative Pain

Enrolled (actual)
110
Serious AEs
0.0%
Results posted
Jul 2016
Primary outcome: Primary: VAS Score Changes ( Cough) During 24 h Postoperatively — 32; 31 mm

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Ropivacaine 0.75 (Drug); Normal saline (Drug)
Age
Adult, Older Adult · 30+ yrs
Sex
All
Sponsor
University of Athens
Primary completion
Jan 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
VAS Score Changes ( Cough) During 24 h Postoperatively
32; 31
SECONDARY
Pain Scores in the Postoperative Care Unit (PACU) at Rest
36; 46
SECONDARY
Pain Scores at Rest 2 h Postoperatively
26; 30
SECONDARY
Pain Scores at Rest 4 h Postoperatively
16; 22
SECONDARY
Pain Scores at Rest 8 h Postoperatively
17; 20
SECONDARY
Pain Scores at Rest 24 h Postoperatively
14; 15
SECONDARY
Pain Scores at Rest 48 h Postoperatively
8; 12
SECONDARY
Pain Scores During Cough in the PACU
42; 55
SECONDARY
Pain Scores During Cough 2 h Postoperatively
36; 55
SECONDARY
Pain Scores During Cough 4 h Postoperatively
25; 34
SECONDARY
Pain Scores During Cough 8 h Postoperatively
29; 34
SECONDARY
Pain Scores During Cough 48 h Postoperatively
18; 26
SECONDARY
Chronic Pain
2; 4
SECONDARY
Chronic Pain
2; 4

Summary

The investigators hypothesis is that perioperative infusion of 0.75 ropivacaine in patients undergoing laparoscopic cholecystectomy may modify the intensity of postoperative pain or the analgesic consumption during the first 24 hours.

Eligibility Criteria

Inclusion Criteria

  • Patients aged 30-70 years American Society of Anesthesiology (ASA) physical status I-III
  • Scheduled for laparoscopic cholecystectomy

Exclusion Criteria

  • Patients with chronic pain and/or on analgesics for the last month,
  • Patients with central nervous, kidney and liver disease, or allergy to local anesthetics
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01388946). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search